Anika Therapeutics (NASDAQ:ANIK) Releases FY 2021 Earnings Guidance

Anika Therapeutics (NASDAQ:ANIK) issued an update on its FY 2021 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $143.50 million-147.42 million, compared to the consensus revenue estimate of $144.15 million.

ANIK stock traded down $0.67 during trading on Thursday, reaching $44.76. The company’s stock had a trading volume of 165,320 shares, compared to its average volume of 129,933. Anika Therapeutics has a 1 year low of $31.55 and a 1 year high of $48.37. The firm has a market cap of $644.14 million, a P/E ratio of -23.68, a P/E/G ratio of 24.26 and a beta of 1.21. The company has a fifty day moving average price of $42.54.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings results on Wednesday, May 5th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.19. Anika Therapeutics had a negative return on equity of 0.98% and a negative net margin of 20.83%. The business had revenue of $34.29 million during the quarter, compared to analyst estimates of $32.39 million. Analysts anticipate that Anika Therapeutics will post 0.19 earnings per share for the current fiscal year.

Separately, Zacks Investment Research upgraded Anika Therapeutics from a sell rating to a hold rating in a research report on Thursday, May 6th.

In other news, Director Raymond J. Land sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, May 12th. The stock was sold at an average price of $42.60, for a total transaction of $85,200.00. Following the completion of the transaction, the director now owns 7,953 shares in the company, valued at $338,797.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.09% of the company’s stock.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses.

Featured Article: How is a buy-side analyst different from a sell-side analyst?

Earnings History and Estimates for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with's FREE daily email newsletter.